X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicines have significantly increased chances of cancer survival around the globe

By Amey Sutkowski  |    May 24, 2017
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to...   Read More

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake

By Holly Campbell  |    February 3, 2017
PhRMA president and CEO Stephen J. Ubl joined Maggie Lake on CNNMoney this week to talk about the industry’s new national campaign, GOBOLDLY™, and meeting with President Donald J. Trump. He also...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

By Hannah Mooney  |    November 14, 2016
Today, there are more than 30 million Americans suffering from type 1 or type 2 diabetes. Roughly 5 percent of patients have type 1 and 90 to 95 percent suffer from type 2, highlighting the...   Read More

Stakeholders raise concerns about ICER’s evidence report for non-small cell lung cancer

By Lauren Neves  |    October 20, 2016
The value of recent advances in non-small cell lung cancer (NSCLC) is undeniable. NSCLC is a devastating illness – 17.7 percent of lung cancer patients survive only five years following their...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

New PhRMA report: New medicines in development for autoimmune diseases offer patients hope for brighter futures

By Hannah Mooney  |    September 12, 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and...   Read More

Patients showcase longer, healthier lives in new “From Hope to Cures” ads

By Ieva M. Augstums  |    September 6, 2016
For Ed, a longer life meant more time with family, friends and his dog, BearBear. When he was diagnosed with colon cancer, he underwent six weeks of radiation, seven months of chemotherapy and 10...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates